IL166214A0 - Combination of chemotherapeutic drugs for increasing antitumor activity - Google Patents
Combination of chemotherapeutic drugs for increasing antitumor activityInfo
- Publication number
- IL166214A0 IL166214A0 IL16621405A IL16621405A IL166214A0 IL 166214 A0 IL166214 A0 IL 166214A0 IL 16621405 A IL16621405 A IL 16621405A IL 16621405 A IL16621405 A IL 16621405A IL 166214 A0 IL166214 A0 IL 166214A0
- Authority
- IL
- Israel
- Prior art keywords
- combination
- antitumor activity
- chemotherapeutic drugs
- increasing antitumor
- increasing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39666702P | 2002-07-17 | 2002-07-17 | |
PCT/US2003/022181 WO2004006909A1 (en) | 2002-07-17 | 2003-07-11 | Combination of chemotherapeutic drugs for increasing antitumor activity |
Publications (1)
Publication Number | Publication Date |
---|---|
IL166214A0 true IL166214A0 (en) | 2006-01-15 |
Family
ID=30116048
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL16621405A IL166214A0 (en) | 2002-07-17 | 2005-01-10 | Combination of chemotherapeutic drugs for increasing antitumor activity |
Country Status (12)
Country | Link |
---|---|
US (1) | US20060089410A1 (xx) |
EP (1) | EP1534262A1 (xx) |
JP (1) | JP2006502117A (xx) |
KR (1) | KR20050040907A (xx) |
CN (1) | CN1681489A (xx) |
AU (1) | AU2003251942A1 (xx) |
CA (1) | CA2492175A1 (xx) |
IL (1) | IL166214A0 (xx) |
MX (1) | MXPA05000555A (xx) |
NZ (1) | NZ537759A (xx) |
WO (1) | WO2004006909A1 (xx) |
ZA (1) | ZA200500418B (xx) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101263121A (zh) | 2005-07-14 | 2008-09-10 | 塔克达圣地亚哥公司 | 组蛋白脱乙酰基酶抑制剂 |
WO2009018233A1 (en) * | 2007-07-30 | 2009-02-05 | Ardea Biosciences, Inc. | Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same |
CA2626679C (en) * | 2005-11-04 | 2011-08-16 | Merck & Co., Inc. | Methods of treating cancers with saha, carboplatin, and paclitaxel and other combination therapies |
EP2451796B1 (en) | 2009-07-08 | 2013-04-17 | Dermira (Canada), Inc. | Tofa analogs useful in treating dermatological disorders or conditions |
US20110153343A1 (en) | 2009-12-22 | 2011-06-23 | Carefusion 303, Inc. | Adaptable medical workflow system |
US20110237686A1 (en) | 2010-03-26 | 2011-09-29 | Cerulean Pharma Inc | Formulations and methods of use |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
US20190046513A1 (en) * | 2017-08-10 | 2019-02-14 | Huya Bioscience International, Llc | Combination therapies of hdac inhibitors and tubulin inhibitors |
EP3778649A4 (en) * | 2018-03-09 | 2022-05-04 | CRAGE medical Co., Limited | METHOD AND COMPOSITION FOR TREATMENT OF TUMOR |
CN111954532A (zh) * | 2018-04-13 | 2020-11-17 | 上海交通大学医学院附属瑞金医院 | 杂芳基酰胺类化合物的抗肿瘤多药耐药性、治疗癌症的用途和蛋白质-药物分子复合物 |
WO2019226519A1 (en) | 2018-05-24 | 2019-11-28 | Celanese EVA Performance Polymers Corporation | Implantable device for sustained release of a macromolecular drug compound |
WO2019222856A1 (en) | 2018-05-24 | 2019-11-28 | Nureva Inc. | Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones |
SG11202005947RA (en) | 2018-05-24 | 2020-07-29 | Celanese Eva Performance Polymers Corp | Implantable device for sustained release of a macromolecular drug compound |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0302349B1 (en) * | 1987-07-30 | 1993-09-29 | Bar Ilan University | Biologically active carboxylic acid esters |
-
2003
- 2003-07-11 MX MXPA05000555A patent/MXPA05000555A/es not_active Application Discontinuation
- 2003-07-11 US US10/521,548 patent/US20060089410A1/en not_active Abandoned
- 2003-07-11 ZA ZA200500418A patent/ZA200500418B/xx unknown
- 2003-07-11 KR KR1020057000884A patent/KR20050040907A/ko not_active Application Discontinuation
- 2003-07-11 CA CA002492175A patent/CA2492175A1/en not_active Abandoned
- 2003-07-11 NZ NZ537759A patent/NZ537759A/en unknown
- 2003-07-11 CN CNA03822108XA patent/CN1681489A/zh active Pending
- 2003-07-11 WO PCT/US2003/022181 patent/WO2004006909A1/en active Application Filing
- 2003-07-11 EP EP03764719A patent/EP1534262A1/en not_active Withdrawn
- 2003-07-11 JP JP2004521887A patent/JP2006502117A/ja active Pending
- 2003-07-11 AU AU2003251942A patent/AU2003251942A1/en not_active Abandoned
-
2005
- 2005-01-10 IL IL16621405A patent/IL166214A0/xx unknown
Also Published As
Publication number | Publication date |
---|---|
CA2492175A1 (en) | 2004-01-22 |
AU2003251942A1 (en) | 2004-02-02 |
US20060089410A1 (en) | 2006-04-27 |
WO2004006909A1 (en) | 2004-01-22 |
NZ537759A (en) | 2006-10-27 |
KR20050040907A (ko) | 2005-05-03 |
JP2006502117A (ja) | 2006-01-19 |
CN1681489A (zh) | 2005-10-12 |
ZA200500418B (en) | 2006-10-25 |
MXPA05000555A (es) | 2005-04-28 |
EP1534262A1 (en) | 2005-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL166214A0 (en) | Combination of chemotherapeutic drugs for increasing antitumor activity | |
AU2003265183A1 (en) | Detection of psychological disorder activity patterns | |
EP1507559A4 (en) | ADMINISTRATION OF MEDICAMENTS CONJUGATED WITH MICRO PARTICLES FOR THE INHIBITION OF STENOSIS | |
IL229156A0 (en) | Treatment of solid tumors by rapamycin derivatives | |
PT1583763E (pt) | Derivados de benzoazolilpiperazina com actividade antagonista de vr1 | |
HK1086830A1 (en) | Heterocyclic compounds and antitumor drugs containing the same as the active ingredient | |
HU0103988D0 (en) | New compounds with pharmaceutical activity | |
HU0103987D0 (en) | New compounds with pharmaceutical activity | |
HK1069526A1 (en) | Anti-influenza drugs | |
HK1089160A1 (en) | 7-imino derivatives of camptothecin having antitumor activity | |
GB0202900D0 (en) | Novel formulations of drugs | |
EP1484061A4 (en) | DRUGS CONTAINING COMPOUNDS OF THE RIBOFLAVIN TYPE | |
IL176061A0 (en) | Nitrooxyderivatives of antihypertensive drugs | |
PL377410A1 (pl) | Leki przeciwko bólowi przewlekłemu | |
AU2002352782A8 (en) | Antitumor activity of bok | |
GB0215593D0 (en) | New anticancer drugs | |
GB0131034D0 (en) | Benzocyclodecane derivatives with antitumor activity | |
GB0327742D0 (en) | Novel uses of known drugs | |
HK1087623A1 (en) | Combination of antidiabetic drugs | |
AU2003274759A1 (en) | Benzofuran compounds having antitumor activity | |
EP1485077A4 (en) | DRUGS COMBINATION THERAPY | |
AU2003224677A8 (en) | Aza-benzothiopyranoindazoles with antitumor activity | |
AU2003225764A8 (en) | Aza-thioxanthenones with antitumor activity | |
GB0427124D0 (en) | Inhibitor of anticancer drug side effect | |
HUP0200109D0 (en) | Compounds having pharmaceutical activity |